CD274 and non-small cell lung carcinoma: Studies have shown that NSCLC patients with early progression on nivolumab have a significantly higher kynurenine/tryptophan ratio, suggesting that IDO might contribute to primary resistance to anti-PD-1/PD-L1 monoclonal antibodies [40].